Zacks.com on MSN3d
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.
GlobalData on MSN3d
Regeneron’s Dupixent approved as first adolescent CRSwNP treatment
The safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.
Nasdaq3d
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved blockbuster drug Dupixent (dupilumab) for the indication of chronic rhinosinusitis with nasal polyps (CRSwNP) for a broader ...
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...
pharmaphorum1d
Dupixent delivers in two skin disease trials
Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...
stocknews12h
3 Genomics Stocks Transforming Healthcare
Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As ...
Mena FN6d
Dupixent® (Dupilumab) Approved In The U.S. As First And Only Treatment For Adolescents With Chronic Rhinosinusitis With Nasal Polyps (Crswnp)
13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab ...